Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor
- 1 March 1998
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 8 (6) , 631-634
- https://doi.org/10.1016/s0960-894x(98)00079-1
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Synthesis, evaluation, and crystallographic analysis of L-371,912: A potent and selective active-site thrombin inhibitorBioorganic & Medicinal Chemistry Letters, 1997
- Rational design of selective thrombin inhibitorsBioorganic & Medicinal Chemistry Letters, 1997
- Design, Synthesis, and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-Argininal Derivatives Incorporating P3-P4 Lactam Sulfonamide MoietiesJournal of Medicinal Chemistry, 1996
- Potent and Selective Thrombin Inhibitors Incorporating the Constrained Arginine Mimic l-3-Piperidyl(N-guanidino)alanine at P1Journal of Medicinal Chemistry, 1996
- Challenges in the development of orally bioavailable thrombin active site inhibitorsBlood Coagulation & Fibrinolysis, 1995
- Design and Synthesis of Potent and Highly Selective Thrombin InhibitorsJournal of Medicinal Chemistry, 1994
- The Venous Antithrombotic Effect of LF 1351 in the Rat following Oral AdministrationThrombosis and Haemostasis, 1992
- The effect of thrombin inhibition in a rat arterial thrombosis modelThrombosis Research, 1991